The global respiratory inhalers market reached $33bn in 2017 and is estimated to reach $38bn by 2023. In 2017, the asthma segment held 58% of the global respiratory inhalers market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 165-page report you will receive 121 charts– all unavailable elsewhere.
The 165-page report provides clear detailed insight into the respiratory inhalers market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Respiratory Inhalers Market from 2018-2028
• Forecast of the Global Respiratory Inhalers market by Type of Product:
• Metered Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs): Single-dose DPIs, Multi-dose DPIs
• Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers
• Forecast of the Global Respiratory Inhalers market by Indication:
• Asthma
• COPD
• Other Respiratory Diseases
• This report provides individual revenue forecasts to 2028 for these national markets:
• The US
• Germany
• France
• UK
• Italy
• Spain
• Japan
• China
• India
• Russia
• Brazil
• Mexico
• Canada
• Our study discusses the selected leading companies that are the major players in the respiratory inhalers market:
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici S.p.A.
• GlaxoSmithKline (GSK)
• Merck & Co.
• Novartis
• Teva
• This report discusses factors that drive and restrain this market. As well as opportunities and challenges faced by this market.
• This report discusses the Porter’s Five Forces Analysis of the respiratory inhalers market.
Visiongain’s study is intended for anyone requiring commercial analyses for the respiratory inhalers market. You find data, trends and predictions.
Buy our report today The Global Respiratory Inhalers Market Analysis : Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Respiratory Inhalers Market Overview
1.2 Global Respiratory Inhalers Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.9.1 Primary Research
1.9.2 Secondary Research
1.9.3 Market Evaluation & Forecasting Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. Introduction to Respiratory Disorders and Therapies
2.1 An Introduction to Respiratory Disorders
2.1.1 Classification of Respiratory Disorders
2.1.2 Asthma
2.1.2.1 Trends in Asthma Prevalence
2.1.2.2 Pathophysiology of Asthma
2.1.2.3 Symptoms of Asthma
2.1.2.4 Treatment of Asthma
2.1.2.5 Guidelines for Asthma Treatment
2.1.2.6 Drug Treatments for Asthma
2.1.3 Chronic Obstructive Pulmonary Disease (COPD)
2.1.3.1 Trends in COPD Prevalence
2.1.3.2 Pathophysiology of COPD
2.1.3.3 Symptoms of COPD
2.1.3.4 Treatment of COPD
2.1.3.5 Drug Treatments for COPD
2.1.3.6 Guidelines for COPD Treatment
2.2 Major Drug Classes in the Treatment of Asthma and COPD
2.2.1 Bronchodilators
2.2.1.1 Beta2-Agonists
2.2.1.2 Anticholinergics
2.2.1.3 Anti-Inflammatory Drugs
2.2.1.4 Corticosteroids
2.2.1.5 Leukotriene Receptor Antagonists
2.2.1.6 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.2.1.7 Combination Drugs
2.2.2 Phases of Clinical Trials
2.2.3 Regulation of Medical Devices
2.2.3.1 The US Approval and Regulation System
2.2.3.2 The EU Approval and Regulation System
2.2.3.3 Post-Marketing Surveillance in the EU
3. Respiratory Inhalers: Global Market Forecast 2018-2028
3.1 The Global Respiratory Inhalers Market in 2018
3.2 Leading Respiratory Inhaler Products
3.3 Leading Companies in the Respiratory Inhalers Market
3.4 Respiratory Inhalers: Trends and Developments
3.4.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.4.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
3.4.3 Telehealth: A Promising Market Trend
3.4.4 Lifecycle Management Strategies to Counter Patent Expiry
3.4.5 Advanced Inhaler Technologies to Counter Generic Erosion
4. Respiratory Inhalers Market by Product Type: Forecast 2018-2028
4.1 Metered Dose Inhalers: Market Forecast 2018-2028
4.2 Dry Powder Inhalers: Market Forecast 2018-2028
4.2.1 Single-Dose DPIs: Market Forecast 2018-2028
4.2.2 Multi-Dose DPIs: Market Forecast 2018-2028
4.3 Nebulizers: Market Forecast 2018-2028
4.3.1 Jet/Compressor Nebulizers: Market Forecast 2018-2028
4.3.2 Ultrasonic Nebulizers: Market Forecast 2018-2028
4.3.3 Vibrating-Mesh Nebulizers: Market Forecast 2018-2028
5. Respiratory Inhalers Market by Indication: Forecast 2018-2028
5.1 Asthma: Market Forecast 2018-2028
5.2 COPD: Market Forecast 2018-2028
5.3 Other Respiratory Diseases: Market Forecast 2018-2028
6. Leading National Markets: Forecast 2018-2028
6.1 Regional Breakdown of the Global Respiratory Inhalers Market
6.2 World Respiratory Inhalers Market Forecast 2018-2028
6.2.1 How will Regional Market Shares Change to 2027?
6.3 The US Respiratory Inhalers Market 2018-2028
6.3.1 The US Respiratory Inhalers Market Forecast 2018-2028
6.3.2 US Respiratory Inhalers Market: Trends and Developments
6.4 EU5 Respiratory Inhalers Market 2018-2028
6.4.1 German Respiratory Inhalers Market Forecast 2018-2028
6.4.2 French Respiratory Inhalers Market Forecast 2018-2028
6.4.3 UK Respiratory Inhalers Market Forecast 2018-2028
6.4.4 Italian Respiratory Inhalers Market Forecast 2018-2028
6.4.5 Spanish Respiratory Inhalers Market Forecast 2018-2028
6.4.6 EU5 Respiratory Inhalers Market: Trends and Developments
6.4.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
6.4.6.2 France: Social Security Finance Bill 2015
6.4.6.3 UK: Improving Asthma and COPD Patient Outcomes
6.4.6.4 Italy: Austerity Measures Limiting Growth
6.4.6.5 Spain: The Start of Recovery in the Spanish Economy
6.5 Japanese Respiratory Inhalers Market 2018-2028
6.6 BRIC Respiratory Inhalers Market 2018-2028
6.6.1 Chinese Respiratory Inhalers Market Forecast 2018-2028
6.6.2 Indian Respiratory Inhalers Market Forecast 2018-2028
6.6.3 Brazilian Respiratory Inhalers Market Forecast 2018-2028
6.6.4 Russian Respiratory Inhalers Market Forecast 2018-2028
6.7 Mexican Respiratory Inhalers Market Forecast 2018-2028
6.8 Canadian Respiratory Inhalers Market Forecast 2018-2028
7. Leading Companies in the Respiratory Inhalers Market
7.1 GlaxoSmithKline (GSK)
7.1.1 GSK: Product Portfolio
7.1.2 GSK: Financial Overview
7.1.3 Recent Developments
7.1.3.1 US FDA Approval for Labelling changes
7.1.3.2 Japanese Regulatory Approval for Relvar Ellipta
7.1.3.3 FDA and Japan Filing of Triple Drug Therapy
7.1.3.4 FDA Approval for Breo Ellipta to Adult Asthma Patients
7.1.3.5 Launch of Combination Drugs
7.1.3.6 GSK Presented Data on Eosinophil Levels and COPD
7.1.3.7 Approval for Arnuity Ellipta
7.1.3.8 Approval for Incruse Ellipta
7.1.3.9 GSK: Products in Development
7.2 AstraZeneca
7.2.1 AstraZeneca: Product Portfolio
7.2.2 AstraZeneca: Financial Overview
7.2.3 Recent Developments
7.2.3.1 Japan Approval for Fasenra (benralizumab)
7.2.3.2 EU Approval for Fasenra (benralizumab)
7.2.3.3 FDA Approval for Fasenra (benralizumab)
7.2.3.4 AstraZeneca and Circassia enter strategic collaboration
7.2.3.5 FDA Approval for Symbicort in Paediatric Patients
7.2.3.6 Charity-Industry Collaboration
7.2.3.7 FDA approval for Bevespi Aerosphere
7.2.3.8 AstraZeneca Acquired Right to Actavis’ Branded Respiratory Portfolio in US and Canada
7.2.3.9 AstraZeneca Acquired Almirall’s Respiratory Portfolio
7.2.3.10 Takeda Respiratory Portfolio Acquisition
7.2.4 AstraZeneca: Products in Development
7.3 Boehringer Ingelheim
7.3.1 Boehringer Ingelheim: Product Portfolio
7.3.2 Boehringer Ingelheim: Financial Overview
7.3.3 Recent Developments
7.3.3.1 Expanded indication for SPIRIVA Respimat in EU
7.3.3.2 Collaboration with Kaohsiung Medical University
7.3.3.3 Collaboration with Weill Cornell Medicine
7.3.3.4 Collaboration with Qualcomm Incorporated
7.3.3.5 Partnership with Propeller Health
7.3.3.6 FDA Approval for Spiriva Respimat
7.3.3.7 Regulatory Approval for Stiolto Respimat
7.3.3.8 Expansion of Respimat Manufacturing Capacity
7.3.3.9 FDA Approval for Stiverdi Respimat
7.3.4 Boehringer Ingelheim: Respiratory Product Pipeline
7.4 Merck & Co. (Merck)
7.4.1 Merck: Product Portfolio
7.4.2 Merck: Financial Overview
7.4.3 Recent Developments
7.4.4 Merck: Products in Development
7.5 Teva
7.5.1 Teva: Product Portfolio
7.5.2 Teva: Financial Overview
7.5.3 Teva: Recent Developments
7.5.3.1 US launch of QVAR REDIHALER
7.5.3.2 FDA Approval for RespiClick
7.5.3.3 European Approval for Aerivio Spiromax
7.5.3.4 FDA Approval for ProAir RespiClick (albuterol sulfate)
7.5.3.5 Acquisition of Gecko Health Innovations
7.5.3.6 Partnership with IBM Watson Health
7.5.4 Teva: Products in Development
7.6 Novartis International AG
7.6.1 Novartis: Product Portfolio
7.6.2 Novartis: Financial Overview
7.6.3 Novartis: Recent Developments
7.6.3.1 Partnership with Propeller Health
7.6.3.2 Exclusive License Agreement with Sunovion Pharma
7.6.3.3 Partnership with Qualcomm Incorporated
7.6.3.4 FDA Approval for Utibron Neohaler
7.6.3.5 Novartis Presented Data on Ultibro and Seebri
7.6.3.6 Pfizer Promotes Two Novartis COPD drugs in the UK
7.6.4 Novartis: Products Under Development
7.7 Chiesi Farmaceutici S.p.A.
7.7.1 Chiesi: Product Portfolio
7.7.2 Chiesi: Financial Overview
7.7.3 Chiesi: Recent Developments
7.7.3.1 Approvals for Trimbow
7.7.3.2 Regulatory Approval for NEXThaler
7.7.3.3 Chiesi: Products Under Development
8. Qualitative Analysis of Respiratory Inhalers Market
8.1 Market Dynamics
8.1.1 Drivers and Opportunities
8.1.1.1 Growing Burden of Respiratory Diseases
8.1.1.2 Smart Inhalers Provide High Growth Opportunities
8.1.1.3 Triple Drug Therapy for COPD To Offer New Revenue Prospects
8.1.2 Restraints and Challenges
8.1.2.1 Patent Expiry and Generic Competition
8.1.2.2 High Cost Impeding Growth of DPIs In Cost-Sensitive Markets
8.2 Porter’s Five Forces Analysis of the Respiratory Inhalers Market
8.2.1 Rivalry among Competitors [Medium]
8.2.2 Threat of New Entrants [Medium]
8.2.3 Power of Suppliers [Medium]
8.2.4 Power of Buyers [High]
8.2.5 Threat of Substitutes [Low]
9. Conclusions
9.1 Respiratory Inhalers: A Maturing Market
9.2 The Global Respiratory Inhalers Market, 2016 - 2028
9.3 Leading Respiratory Inhalers
9.4 Leading Respiratory Inhaler Companies
9.5 Leading Regional and National Markets
9.6 Global Respiratory Inhalers Market Forecast, 2018-2028
9.7 The Future of Respiratory Inhalers Market
Appendices
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Figures
Figure 1.1 Ageing Population Estimates 2010 - 2050
Figure 1.2 Global Respiratory Inhalers: Market Segmentation
Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016
Figure 2.2 Summary of GOLD Guidance for COPD Treatment
Figure 3.1 World Respiratory Inhalers Market: Market Shares (%) for Major National Markets
Figure 3.2 Top 5 Respiratory Inhalers: Market Shares (%), 2016
Figure 4.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028
Figure 4.2 Metered Dose Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028
Figure 4.4 Single-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 4.5 Multi-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 4.6 World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Figure 4.7 World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Figure 4.8 World Vibrating-Mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Figure 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Disease Indication, 2016-2028
Figure 5.2 World Asthma Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 5.3 World COPD Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 5.4 World Respiratory Inhalers Market for Other Diseases, Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.1 Respiratory Inhalers Market: Revenues ($m) by Region, 2018
Figure 6.2 World Respiratory Inhalers Market: Market Shares (%) by Region, 2018
Figure 6.3 World Respiratory Inhalers Market Forecast: Revenues ($m) by Region, 2016-2028
Figure 6.4 World Respiratory Inhalers Market: Market Shares (%) by Region, 2018
Figure 6.5 World Respiratory Inhalers Market: Market Shares (%) by Region, 2023
Figure 6.6 World Respiratory Inhalers Market: Market Shares (%) by Region, 2028
Figure 6.7 US Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.8 EU5 Respiratory Inhalers Market Forecast: Revenues ($m) by National Market, 2016-2028
Figure 6.9 German Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.10 French Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.11 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 6.12 Italian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.13 Spanish Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.14 Japanese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.15 BRIC Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.16 Chinese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.17 Indian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.18 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.19 Russian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.20 Mexican Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 6.21 Canadian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
Figure 7.1 GSK: Major Respiratory Inhalers Revenue ($m), 2017
Figure 7.2 GSK: Major Respiratory Inhalers Revenue Share (%) by Product, 2017
Figure 7.3 GSK: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
Figure 7.4 AstraZeneca: Major Respiratory Inhalers Revenue ($m), 2017
Figure 7.5 AstraZeneca: Major Respiratory Inhalers Revenue Share (%), by Product, 2017
Figure 7.6 AstraZeneca: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
Figure 7.7 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), 2017
Figure 7.8 Boehringer Ingelheim: Major Respiratory Inhalers Revenue Share (%), by Product, 2017
Figure 7.9 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
Figure 7.10 Merck: Major Respiratory Inhalers Revenue ($m), 2017
Figure 7.11 Merck: Major Respiratory Inhalers Revenue Share (%) by Product, 2017
Figure 7.12 Merck: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
Figure 7.13 Teva: Major Respiratory Inhalers Revenue ($m), 2017
Figure 7.14 Teva: Major Respiratory Inhalers Revenue Share (%) by Product, 2017
Figure 7.15 Teva: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
Figure 7.16 Novartis: Major Respiratory Inhalers Revenue ($m), 2017
Figure 7.17 Novartis: Major Respiratory Inhalers Revenue Share (%), by Product, 2017
Figure 7.18 Novartis: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
Figure 7.19 Chiesi: Foster Inhaler Revenue ($m) and AGR (%), 2016-2028
Figure 8.1 Porter’s Five Forces Analysis of the Respiratory Inhalers Market, 2016-2028
Figure 9.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028
List of Tables
Table 2.1 Classification of Respiratory Diseases
Table 2.2 Clinical Trial Phases
Table 3.1 Top 5 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2017
Table 4.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Product Type, 2016-2028
Table 4.2 World Metered Dose Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028
Table 4.4 Types of Marketed Breezhaler Devices
Table 4.5 Single-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.6 Multi-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.7 World Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Type, 2016-2028
Table 4.8 World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.9 World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.10 World Vibrating-Mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Disease Indication, 2016-2028
Table 5.2 World Asthma Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 5.3 World COPD Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 5.4 World Respiratory Inhalers Market for Other Diseases, Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.1 World Respiratory Inhalers Market: Revenues ($m) and Market Shares (%) by Region, 2018
Table 6.2 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2028
Table 6.3 Market Shares (%) of Leading Regional Respiratory Inhalers Markets, 2016, 2022 and 2027
Table 6.4 US Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.5 EU5 Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2028
Table 6.6 German Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.7 French Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.8 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.9 Italian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.10 Spanish Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.11 Japanese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.12 BRIC Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.13 Chinese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.14 Indian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.15 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.16 Russian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.17 Mexican Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 6.18 Canadian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
Table 7.1 GSK: Overview, 2017
Table 7.2 GSK: Respiratory Inhaler Products
Table 7.3 GSK: Major Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type,2016-2028
Table 7.4 GSK: Respiratory Therapies Pipeline, 2017
Table 7.5 AstraZeneca: Overview, 2017
Table 7.6 AstraZeneca: Respiratory Inhaler Products
Table 7.7 AstraZeneca: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028
Table 7.8 AstraZeneca: Respiratory Therapies Pipeline, 2017
Table 7.9 Boehringer Ingelheim: Overview, 2017
Table 7.10 Boehringer Ingelheim: Respiratory Inhaler Products
Table 7.11 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028
Table 7.12 Merck: Overview, 2017
Table 7.13 Merck: Respiratory Inhaler Products
Table 7.14 Merck: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
Table 7.15 Teva: Overview, 2017
Table 7.16 Teva: Respiratory Inhaler Products
Table 7.17 Teva: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
Table 7.18 Teva: Respiratory Product Pipeline,2017
Table 7.19 Novartis: Overview, 2017
Table 7.20 Novartis: Respiratory Inhaler Products
Table 7.21 Novartis: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
Table 7.22 Novartis: Respiratory Product Pipeline, 2016
Table 7.23 Chiesi: Overview, 2017
Table 7.24 Chiesi: Respiratory Inhaler Products
Table 7.25 Chiesi: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
Table 9.1 Top 10 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2017
